Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.52 |
| ▸ | JAK2 | O60674 | 16/20 | 0.52 |
| ▸ | JAK1 | P23458 | 15/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855941 | 1.00 | TYK2 (0.52) | TYK2JAK2JAK1AURKALCK | |
| SCHEMBL22856034 | 1.00 | TYK2 (0.52) | TYK2JAK2JAK1AURKALCK | |
| SCHEMBL22855942 | 0.88 | TYK2 (0.69) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL29597698 | 0.88 | TYK2 (0.69) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL24276489 | 0.84 | AURKA (0.53) | TYK2JAK2JAK1AURKALCK | |
| SCHEMBL29414207 | 0.84 | AURKA (0.53) | TYK2JAK2JAK1AURKALCK | |
| SCHEMBL22855940 | 0.84 | JAK2 (0.67) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL29414214 | 0.83 | AURKA (0.48) | TYK2JAK2JAK1AURKAAURKB | |
| SCHEMBL22856023 | 0.75 | JAK2 (0.43) | TYK2JAK2JAK1JAK3FLT3 | |
| SCHEMBL29566873 | 0.75 | JAK2 (0.43) | TYK2JAK2JAK1JAK3FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3990449-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | Guangzhou InnoCare Pharma Tech Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-114096532-A | Heterocyclic compounds inhibiting tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | TYK2 1/4885JAK2 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.